{"id":"W4297821473","doi":"10.1016/j.annonc.2022.08.025","title":"LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Takeda Oncology; EMD Serono; Eisai Canada; Ipsen; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Verastem Oncology; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; Clovis Oncology; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Meso Scale Diagnostics; Merck Sharp and Dohme; KU Leuven; Pfizer; Incyte; F. Hoffmann-La Roche; Seagen; Roche; Carrick Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Bevacizumab; Olaparib; Clinical endpoint; Population; Progression-free survival; Oncology; Ovarian cancer; BRCA mutation; Cancer; Chemotherapy; Gastroenterology; Randomized controlled trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00143862,0.000700822,0.001247481,0.0003077193,0.0002467925,0.0008547874,0.0005366333,0.0006212531,0.004484775],"category_scores_gemma":[0.001084438,0.0002077508,0.001636974,0.000375205,0.0003574206,0.0005064322,0.0003919164,0.002131492,0.000819182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007047686,"about_ca_system_score_gemma":0.000863554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001364769,"about_ca_topic_score_gemma":0.0046131,"domain_scores_codex":[0.9996785,0.0001721077,0.00001668897,0.00004669027,0.00003504438,0.00005105691],"domain_scores_gemma":[0.9994434,0.0001478522,0.0001037875,0.00003290104,0.00003615451,0.0002360583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7321767,0.008814165,0.01724876,0.002217861,0.004752877,0.0002395388,0.0001284766,0.005911934,0.02004773,0.0006672461,0.02672878,0.181066],"study_design_scores_gemma":[0.556141,0.2700903,0.1200644,0.0004224142,0.007617775,0.0006877432,0.0001382461,0.005721388,0.005417997,0.001636493,0.03196478,0.00009743455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.946112,0.0154565,0.001055682,0.00213968,0.0004900901,0.001829762,0.01957554,0.0002369828,0.01310391],"genre_scores_gemma":[0.9545452,0.004838631,0.001656644,0.001914244,0.0002639348,0.00136846,0.02941447,0.00007598801,0.005922467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004484775,"threshold_uncertainty_score":0.01500309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1353292322808456,"score_gpt":0.4284463903092336,"score_spread":0.293117158028388,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}